Newly Diagnosed Clinical Trials

7 recruiting

Newly Diagnosed Trials at a Glance

46 actively recruiting trials for newly diagnosed are listed on ClinicalTrialsFinder across 6 cities in 42 countries. The largest study group is Phase 2 with 23 trials, with the heaviest enrollment activity in Suzhou, Paris, and New York. Lead sponsors running newly diagnosed studies include The First Affiliated Hospital of Soochow University, Institute of Hematology & Blood Diseases Hospital, China, and Fujian Medical University Union Hospital.

Browse newly diagnosed trials by phase

Treatments under study

About Newly Diagnosed Clinical Trials

Looking for clinical trials for Newly Diagnosed? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Newly Diagnosed trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Newly Diagnosed clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 46 trials

Recruiting
Phase 2

18F-Fluciclovine PET/CT in Multiple Myeloma

Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Relapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI)60 enrolled1 locationNCT06103838
Recruiting
Phase 4

Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).

Acute Myeloid LeukemiaChemotherapy EffectNewly Diagnosed
Fujian Medical University Union Hospital100 enrolled1 locationNCT07561892
Recruiting
Phase 2

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Central Nervous System DiseasesBrain CancerGlioblastoma Multiforme (GBM)+4 more
Black Diamond Therapeutics, Inc.162 enrolled4 locationsNCT07326566
Recruiting
Phase 3

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Amgen304 enrolled192 locationsNCT04994717
Recruiting
Phase 2

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

Multiple Myeloma (MM)Multiple Myeloma, Newly Diagnosed
SCRI Development Innovations, LLC100 enrolled11 locationsNCT06974786
Recruiting
Phase 3

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

Multiple MyelomaNewly Diagnosed Multiple Myeloma
GlaxoSmithKline520 enrolled181 locationsNCT06679101
Recruiting
Phase 2

Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia

Elderly PatientsNewly Diagnosed Acute Myeloid Leukemia (AML)
Chinese PLA General Hospital120 enrolled1 locationNCT07514936
Recruiting
Phase 3

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

Multiple Myeloma, Newly Diagnosed
Intergroupe Francophone du Myelome824 enrolled64 locationsNCT06918002
Recruiting

A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve Prostate Cancer

Newly Diagnosed, Treatment-naïve Prostate Cancer
Xijing Hospital1,000 enrolled9 locationsNCT07474142
Recruiting
Phase 1Phase 2

New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study

Newly Diagnosed Glioblastoma
Assistance Publique - Hôpitaux de Paris35 enrolled5 locationsNCT06622434
Recruiting

Oncology, Undernutrition and Sensoriality: Links, Mechanisms and Levers for Action

Newly Diagnosed Cancer of the Oropharynx, Oral Cavity, Colon or Liver
Centre Hospitalier Universitaire Dijon306 enrolled1 locationNCT06600295
Recruiting
Phase 2

Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML

Newly Diagnosed Acute Myeloid Leukemia (AML)Intensive Chemotherapy UnfitAge ≥60
First Affiliated Hospital of Zhejiang University25 enrolled5 locationsNCT07172204
Recruiting
Phase 1

A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma

Glioblastoma (GBM)Newly Diagnosed Glioblastoma Multiforme
CHA University10 enrolled1 locationNCT07143812
Recruiting

Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia

Acute LeukemiaNewly DiagnosedRelapsed
Memorial Sloan Kettering Cancer Center1,365 enrolled3 locationsNCT02677064
Recruiting
Phase 2

Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab

Newly Diagnosed Glioblastoma
Duke University92 enrolled1 locationNCT06816927
Recruiting

Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients

Newly Diagnosed Multiple Myeloma (NDMM)
Peking University People's Hospital500 enrolled1 locationNCT07296627
Recruiting
Phase 2

Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia, AdultNewly Diagnosed
The First Affiliated Hospital of Soochow University172 enrolled1 locationNCT06532552
Recruiting
Phase 2

Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia

Newly DiagnosedAcute Monocytic Leukemia
The First Affiliated Hospital of Soochow University92 enrolled1 locationNCT05566054
Recruiting
Phase 1Phase 2

D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

Newly Diagnosed MGMT Unmethylated Glioblastoma
Darell Bigner50 enrolled1 locationNCT05734560
Recruiting
Phase 2

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Glioblastoma MultiformeNewly Diagnosed GlioblastomaGlioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype+1 more
Northwestern University25 enrolled1 locationNCT05864534